Calquence (acalabrutinib)

pCPA File Number: 21413
Negotiation Status:
Concluded with an LOI
Indication(s):
Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
Sponsor/Manufacturer:
AstraZeneca Canada Inc.
CDA-AMC Project Number:
PC0211-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: